Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Paycom Software Inc (PAYC) vs Pfizer Inc (PFE) Price & Performance

Paycom Software IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Paycom Software Inc vs Pfizer Inc — how do they compare? Paycom Software Inc trades at $214.7 (market cap $9.88B), while Pfizer Inc trades at $27.85 (market cap $158.39B). The key difference: Pfizer Inc is far larger — about 16× Paycom Software Inc's market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.

PAYCPFE
Market Cap
$9.88B$158.39B
Sector
TechnologyHealth
52-Week High
$240.52$29.02
52-Week Low
$113.59$23.60
Enterprise Value
$10.66B$209.89B
Dividend Yield
0.68%6.19%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Paycom Software Inc

Paycom Software (PAYC) trades at $219.16, down 5.4% today but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal despite recent weakness, supported by positive analyst sentiment and institutional accumulation. Recent Q2 2026 results exceeded expectations with EPS of $2.78 beating estimates of $2.38, driving management's raised full-year guidance.

Outlook remains positive with a consensus price target of $231.70 offering 5.7% upside potential. Key opportunities include sustained revenue growth and expanding margins, while risks involve competitive pressures and market volatility. The company's strong cash flow generation and shareholder returns through dividends and buybacks support long-term value creation.

Pfizer Inc

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Paycom Software Inc

Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.

Read more on PAYC

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE